Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 3Lymphoma, Non-Hodgkin 2Leukemia 2Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Pain 1Lymphoma, T-Cell 1Lymphoma 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 10fludarabine 7pomalidomide 5pembrolizumab 5Dexamethasone 5daratumumab 4obinutuzumab 3glofitamab 3fludarabine phosphate 3abemaciclib 3Rituximab 3Melphalan 3Immunotherapy, Adoptive 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2pirtobrutinib 2palbociclib 2cemiplimab 2blinatumomab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Nivolumab 2Mesna 2Letrozole 2Injections 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pegfilgrastim × 30 days × Clear all
NCT01840566 2026-05-28

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡